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ABSTRACT
Effective stimulation of immune cells is crucial for the success of cancer 
immunotherapies. Current approaches to evaluate the efficiency of stimuli are 
mainly defined by known flow cytometry-based cell activation or cell maturation 
markers. This method however does not give a complete overview of the achieved 
activation state and may leave important side effects unnoticed. Here, we used an 
unbiased RNA sequencing (RNA-seq)-based approach to compare the capacity of 
four clinical-grade dendritic cell (DC) activation stimuli used to prepare DC-vaccines 
composed of various types of DC subsets; the already clinically applied GM-CSF and 
Frühsommer meningoencephalitis (FSME) prophylactic vaccine and the novel clinical 
grade adjuvants protamine-RNA complexes (pRNA) and CpG-P. We found that GM-CSF 
and pRNA had similar effects on their target cells, whereas pRNA and CpG-P induced 
stronger type I interferon (IFN) expression than FSME. In general, the pathways 
most affected by all stimuli were related to immune activity and cell migration. GM-
CSF stimulation, however, also induced a significant increase of genes related to 
nonsense-mediated decay, indicating a possible deleterious effect of this stimulus. 
Taken together, the two novel stimuli appear to be promising alternatives. Our study 
demonstrates how RNA-seq based investigation of changes in a large number of genes 
and gene groups can be exploited for fast and unbiased, global evaluation of clinical-
grade stimuli, as opposed to the general limited evaluation of a pre-specified set of 
genes, by which one might miss important biological effects that are detrimental for 
vaccine efficacy.
INTRODUCTION
Antigen presenting cells, such as Dendritic cells 
(DCs), play a central role in many immunotherapies 
because of their ability to induce immune responses or 
to promote immune tolerance by interacting with CD4+ 
and CD8+ T cells. For T cell activation to occur, DCs 
need to mature and migrate to the lymph nodes. DC 
immunotherapies aim to strengthen antitumoral immune 
responses by boosting T cell activation [1, 2]. In such 
therapies, DCs are isolated, activated and loaded with 
tumor antigen and then given back to the patient. Vaccine 
DCs are anticipated to promote antitumor responses by 
presenting tumor antigen in the context of costimulatory 
molecules and immune-stimulatory cytokines [3-7]. 
Upon activation, DCs upregulate costimulatory markers 
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like CD40 and CD80, but also co-inhibitory markers, 
such as PD-L1, PD-L2, IL-10 and TGF-β, which are 
essential for the termination of an immune response. 
Expression of the right maturation markers and secretion 
of the right cytokines is thus important for vaccine 
success and these therefore need to be taken into account 
when selecting the optimal adjuvant for the activation of 
vaccine DCs.
We perform immunotherapies with naturally 
occurring DCs, namely CD1c+ myeloid dendritic cells 
(mDCs) and plasmacytoid dendritic cells (pDC) [8, 9]. 
These two subsets possess complementary phenotypes: 
they secrete different cytokines, express different pattern 
recognition receptors (PPR), and even take different, 
incompletely understood, migratory routes [10-14]. 
Mature plasmacytoid DCs respond to viruses and are 
known to produce large amounts of type I IFNs upon 
activation and may also induce T cell responses [15-
20]. Their counterparts, the CD1c+ mDCs, respond to 
various microbial and fungal stimuli and induce Th1 
responses via the production of IL-12 upon maturation 
[11, 21-23]. Successful activation of naïve CD8+ T cells 
to cytotoxic CD8+ lymphocytes (CTLs) is of high interest 
for immunotherapies, since CTLs specifically target the 
cancerous cells [24, 25]. In several clinical studies, the 
presence of CTLs was associated with a higher survival 
or increased clinical response [26-28]. Taken together, 
because both DC subsets are able to provoke a Th1 
response, combining them may increase the efficacy of the 
antitumor immune response. Our clinical trials with either 
pDCs, stimulated by FSME (an inactivated tick borne 
encephalitis virus that most likely binds to TLR7/8), or 
with CD1c+ mDCs using GM-CSF (a growth factor that 
promotes myeloid cell maturation), highlighted the anti-
tumor potential and positive clinical outcome in melanoma 
patients [8, 9].
The only available good manufacturing practice 
(GMP) grade TLR7/8 ligand is pRNA, a complex of 
protamine and mRNA, which most likely triggers 
TLR7/8, similar to FSME [29]. Sköld et al. have recently 
shown that pRNA activates CD1c+ mDCs and pDCs and 
induces them to release IL-12 and IFN-α, respectively, 
making it a promising candidate to use for vaccines 
containing both subsets [30]. These findings prompted us 
to further inspect the effect of pRNA on DC activation. 
Furthermore, we investigated another novel clinical 
grade pDC activation stimulus, CpG-P. CpG ODNs 
are short single-stranded DNA molecules containing 
unmethylated CpG dinucleotides and can be divided 
in different classes depending on their effects. CpG-C 
and CpG-P combine both effects of CpG-A and CpG-B, 
namely strong IFN-α release and strong maturation 
marker upregulation [31, 32].
In our study we obtained and analyzed RNA 
sequencing data of the two DC subsets using these 
new clinical grade adjuvants conditions to obtain a 
comprehensive and unbiased overview of the effect 
of each stimulus on the phenotype of the activated 
DCs. Focusing only on specific maturation markers 
and cytokines may lead to a loss of relevant findings. 
Recently, the relevance of implementing systems biology 
in vaccine research has been demonstrated by studying 
the effect of human adjuvants in animal models with 
transcriptome profiling [33-35]. Because of its unbiased 
nature, system vaccinology may help to understand 
which immunological processes are detrimental for 
vaccine success [36-38]. In the present study, we applied 
principal coordinate analysis (PCoA) and gene ontology 
(GO) analysis to evaluate the effect of each adjuvant 
on the whole cell rather than selected maturation 
markers and cytokines only. Using these approaches, 
we compared the previously used DC activation stimuli, 
GM-CSF for CD1c+mDCs and FSME for pDCs, with the 
novel stimuli, pRNA and CpG-P, and validated several 
of our findings with functional assays. Our data indicate 
that both pRNA and CpG-P are suitable clinical grade 
adjuvants for the activation of either both DC subsets 
together or pDCs alone.
RESULTS
RNA-seq gene expression levels are comparable 
with protein levels
To evaluate the transcriptome of the two DC 
subsets upon activation with different stimuli, we 
performed whole-cell RNA sequencing of magnetic bead 
isolated CD1c+ mDCs and pDCs of the same donors. 
To this aim, DC transcriptomes were analyzed directly 
after isolation or following 6 hours of stimulation with 
either IL-3 alone, FSME and IL-3 or pRNA and IL-3 
(pDCs) or GM-CSF, pRNA (CD1c+ mDCs). First, 
we were interested in whether this approach would 
give comparable results as targeted flow cytometry 
evaluation of established DC maturation markers. Here 
we chose the markers CD80, PDL-1, and CD40 (Figure 
1A–1C) as representatives for the maturation state of 
these DC subsets. CD80 is a co-stimulatory maturation 
marker also used in our clinical set up to determine the 
maturation state of the DCs [8, 39]. PD-L1 as a co-
inhibitory and CD40 as an additional co-stimulatory 
marker were considered suitable candidates to complete 
the set, because both maturation markers are known to 
be expressed on both cell subsets [40]. Comparing the 
different conditions of pDCs with each other, we found 
that the overall pattern of RNA and protein expression 
was similar. The survival factor IL-3 showed no or very 
little effect on the expression of the maturation markers, 
except on CD40 (Figure 1C). FSME and pRNA, showed 
a similar upregulation of maturation markers CD80, 
PDL-1 and CD40 on pDCs. In CD1c+ mDCs, GM-
CSF or pRNA caused an upregulation of all maturation 
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Figure 1: RNA-seq results represent protein levels. A. Flow cytometry histograms for three maturation markers (CD80, PD-L1 
and CD40) on pDCs and CD1c+ mDCs. For CD1c: Light grey represents unstimulated samples, dark grey represents GM-CSF samples, 
and black represents pRNA samples. For pDC: bright transparent grey represents the unstimulated samples, light grey represents the 
IL-3 samples, grey represents FSME and black represents pRNA samples. B. Gene expression levels of the 3 donors of the RNA-seq. 
C. Correlation plot of the RNA-seq counts/1 million reads set out against the geometric mean fluorescence intensity as measured by flow 
cytometry (protein level). Throughout this paper, error bars represent standard error of the mean.
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markers, at both RNA and protein levels. However, there 
were some differences in the strength of the two stimuli: 
pRNA appeared to have a stronger affect on CD80 and 
PD-L1 RNA and protein expression. GM-CSF induced 
stronger CD40 RNA expression but this was not found at 
the protein level. In order to further delineate the relation 
between RNA-seq reads and protein expression levels, 
we performed a Spearman nonparametric correlation 
analysis with the RNA sequencing samples of the 3 
donors and compared them to protein expression values 
of 6 different donors. All three maturation markers 
showed strong correlations between RNA and protein 
levels (CD80: r2=0.902, p=0.00545; PD-L1: r2=0.814, 
p=0.026; CD40: r2=0.822, p=0.0232). Altogether, RNA 
seq data well reflected flow cytometry data indicating 
the biological relevance of changes in RNA expression 
values. Furthermore, this first analysis suggests that 
pRNA is equally or even more potent than currently used 
clinical grade stimuli in the activation of CD1c+ mDCs 
and pDCs.
Clinical grade stimuli have similar overall effects 
on both cell types
Having confirmed the validity of RNA-seq for 
evaluating DC maturation status, we were interested in how 
specific stimuli affect the entire DC transcriptome, rather than 
a small pre-defined set of maturation markers. Therefore, 
we applied principal coordinates analysis (PCoA) on the 
gene expression data of all DC types and conditions tested, 
separately per donor. The first two principal coordinates are 
shown in Figure 2A. The first coordinate (X axis) aligned 
roughly with the cell type (pDC versus CD1c+ mDC), 
whereas the second coordinate reflected maturation status. 
The overall picture was similar between the three donors, 
indicating good reproducibility of the RNA sequencing.
Figure 2: RNA-seq-based global assessment of DC responses to clinical stimuli. A. Principal coordinates analysis (PCoA) 
of pDCs and CD1c+ mDCs was performed for each of the stimuli to compare their similarities in gene expression. Each point represents 
the transcriptome of the respective condition and the analysis was based on the first and second coordinate. On the x-axis the principle 
coordinate one (PCO1) is displayed, on the y-axis the principle coordinate two (PCO2). B. Correlation plots depicting the gene expression 
changes upon each stimulus for each subset. Each point represents a gene.
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In both DC subsets the new stimulus, pRNA, 
showed a similar effect as the previously used stimuli 
FSME and GM-CSF. While the differences in effects 
between GM-CSF and pRNA, as measured by the first two 
principal coordinates, were very small for CD1c+ mDCs, 
the differences between stimuli were more pronounced 
on pDCs. Using the unstimulated pDCs as the reference 
point, the FSME sample and pRNA did align along the 
same axis, but pRNA was located further away from the 
unstimulated cells. This suggests that both stimuli affect 
the RNA expression of roughly the same genes, but that 
pRNA has an overall stronger effect on these genes. 
Furthermore, the data indicated that upon stimulation, the 
differences between the two DC phenotypes increased.
To directly compare the established and the novel 
stimuli for each of the two cell types, we correlated the 
fold-changes of each gene relative to unstimulated cells 
(for CD1c+ mDCS) or to IL3-treated cells (for pDCs) of 
existing and novel activation stimuli (Figure 2B). Both 
plots confirmed the overall similar effect of the existing 
and novel stimuli on the transcriptome we already 
observed by PCoA. In line with PCoA, a slight skewing 
of the pDC correlation plot towards pRNA indicated 
that indeed pRNA had a stronger effect than FSME on 
mostly the same set of genes. Interestingly, for pDCs more 
genes were highly upregulated (>10 fold) than highly 
downregulated by both stimuli, whereas for CD1c+ mDCs 
this difference was less pronounced (Figure 2B).
To find out which biologically coherent gene 
groups were most affected by the different stimuli, a gene 
ontology (GO) term analysis was performed (Table 1) on 
all significantly (p<0.05 after multiple testing correction 
with the Benjamini-Hochberger method) up- and 
downregulated genes of each subset. This qualitative 
method also provided insight in affected pathways and 
gene groups not directly connected to DC maturation. 
Overall, all stimuli most strongly affected immune 
response-related genes. However, GM-CSF treatment 
of CD1c+ mDCs also clearly affected a number of gene 
clusters that are not directly linked to immune response. 
Of note, one of these clusters was “nonsense-mediated 
decay” [41], pointing to a possible deleterious effect.
Together, the whole-transcriptome analysis 
indicated that pRNA had similar effects on both cell types 
as the existing cell type-specific stimuli. However, pRNA 
appeared to have an overall stronger maturation effect on 
pDCs and a similar effect on CD1c+ mDCs compared to 
the previously used stimuli. Importantly, unlike GM-CSF, 
pRNA did not have any obvious negative effects on CD1c+ 
mDCs.
Discrepancies between pRNA stimulated pDCs 
and CD1c+ mDCs
Besides the overall similarities among used stimuli, 
we also observed differences between the effects of 
the existing and novel stimuli on each cell subset. A 
limitation of the GO term analysis is that it does not take 
into account the magnitude of the expression changes 
and therefore no conclusions on these can be drawn. 
Therefore, as a complementary approach, we generated 
Volcano plots of the overall fold-changes and p-values for 
each gene based on the combined data from all 3 donors. 
These plots show that pRNA in CD1c+ mDCs caused a 
strong upregulation of cytokines and migration-related 
genes (Figure 3). In CD1c+ mDCs stimulated with GM-
CSF, several chemokines (CXCL5, CCL1 CSF1, CCL24 
and CCL22) were upregulated 12-13 fold. Upon activation 
with pRNA, chemokines were once again found among the 
most upregulated genes. Except for CXCL5 and CCL17, 
these genes were upregulated to a very similar extent as 
upon GM-CSF stimulation. Comparing the chemokines 
with each other, the fold changes were almost on the same 
level between the two stimuli (Figure 3A and 3B).
In pDCs, multiple genes related to type I and III 
interferons (IFN-α and IFN-λ) were found among the 
most strongly and significantly upregulated genes. While 
pRNA lead to a significant increase of the transcription 
of various subtypes of IFN-α and IFN-λ (IL28/ IL29), 
FSME upregulated the chemokines CXCL9, CXCL10 
and CXCL11 when compared to unstimulated pDCs. 
As already indicated by PCoA and correlation plots 
(Figure 2), the overall extent of gene expression increase 
upon FSME was less than upon pRNA stimulation. For 
instance, whereas FSME caused a >10-fold increase for 
only 3 genes, pRNA did so for 26 genes. Several IFN-α 
subtypes showed 13-fold increases when stimulated with 
pRNA, compared to 9- to 10-fold for FSME (Figure 3C 
and 3D). As expected the difference between DC subtypes 
was most prominent for type I IFNs, pRNA induced no 
IFN-α production in CD1c+ mDCs in contrast to high 
levels in pDCs. In pDCs, all 13 type I IFN genes were 
upregulated upon pRNA stimulation in all 3 donors 
(Figure 4A). We confirmed this observation at the protein 
level in 7 donors and detected a significantly higher (10-
fold, p<0.001) release of IFN-α upon pRNA compared to 
FSME stimulation (Figure 4B).
To assess the effect of pRNA on CD1c+ mDC, we 
assessed additional immunostimulatory cytokines that are 
known to be relevant for this subset. Based on the RNA-
seq data, the gene expression of the immunostimulatory 
cytokines IL-12p40, IL-23 and IL-6 increased significantly 
upon pRNA stimulation (Figure 5A). TNF-α, another 
immunostimulatory cytokine, was increased on both 
pDCs and (less strongly) on CD1c+ mDCs. Additionally, 
the transcription of the immunoinhibitory cytokine IL-
10 increased by pRNA stimulation compared to the 
unstimulated and GM-CSF-stimulated samples. We chose 
IL12p70 and TNF-α as representing cytokines to confirm 
the RNA-seq results on the protein level (Figure 5B). IL-
12p70 release showed the same pattern as the RNA-seq 
counts, whereas for TNF-α release the results differed 
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Table 1: Clinical stimuli affect similar gene clusters in pDCs but less so in CD1c+ mDCs 
term ontology N genes N up/down - log_10 p-value
CD1c+ mDC GM-CSF
cytosolic ribosome CC 103 62 25.4
extracellular region part CC 3752 755 22.5
SRP-dependent cotranslational protein targeting to membrane BP 108 60 22.1
cotranslational protein targeting to membrane BP 110 60 21.5
nuclear-transcribed mRNA catabolic process, nonsense-mediated 
decay
BP 120 63 21.4
immune system process BP 2576 547 20.6
protein targeting to ER BP 114 60 20.5
extracellular region CC 4482 862 20.0
establishment of protein localization to endoplasmic reticulum BP 118 60 19.5
regulation of multicellular organismal process BP 2403 507 18.4
CD1c+ mDC pRNA
immune system process BP 2576 578 21.3
regulation of cell migration BP 593 177 17.8
cell surface receptor signaling pathway BP 2677 580 17.8
regulation of cell motility BP 628 184 17.6
immune response BP 1626 383 17.2
regulation of cellular component movement BP 704 199 17.1
inflammatory response BP 616 180 17.1
extracellular region part CC 3752 764 16.6
response to organic substance BP 2828 601 16.5
regulation of locomotion BP 690 194 16.4
pDC FSME
immune response BP 1626 127 26.9
immune system process BP 2576 165 25.9
response to type I interferon BP 85 30 24.7
response to virus BP 403 57 23.7
type I interferon signaling pathway BP 84 29 23.6
cellular response to type I interferon BP 84 29 23.6
defense response to virus BP 325 51 23.3
response to biotic stimulus BP 904 85 22.7
response to external biotic stimulus BP 869 82 22.0
response to other organism BP 869 82 22.0
pDC pRNA
response to virus BP 403 73 24.4
immune response BP 1626 166 24.3
(Continued )
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slightly from the RNA-seq data: On protein level, pRNA 
was the most effective stimulus for TNF-α production on 
both cell types, whereas the RNA-seq counts suggested 
GM-CSF as a slightly more potent TNF-α stimulus.
Taken together, our results suggest pRNA to be a 
potent activation stimulus for pDCs as well as CD1c+ 
mDCs, reflected by a strong upregulation of type I IFN 
and chemokines.
CpG-P as a clinical grade stimulus for pDCs
Finally, we investigated CpG-P, a novel clinical grade 
TLR9 agonist, as a pDC-specific activator. These synthetic 
oligonucleotides mimic the effect of bacterial DNA and 
therefore may support Th1 responses. We used RNA-seq on 
pDCs from two donors to evaluate the effect of CpG-P on 
pDCs and validated our findings with additional functional 
assays on protein level. For that purpose, we incorporated 
the CpG-P stimulated pDC samples into the PCoA analysis 
and evaluated their positions. The CpG-P samples appeared 
to be similar to pRNA in Donor 2 and close to both pRNA 
and FSME in Donor 3 regarding overall gene expression 
levels (Figure 6A). These results suggested that CpG-P 
is a strong activation stimulus for pDCs. To get a more 
detailed view of the changes in gene expression of DC-
specific genes, we focused on the DC maturation markers 
shown in Figure 1. CpG-P induced a stronger upregulation 
of transcripts and proteins of all 3 maturation markers 
than FSME and pRNA (Figure 6B & 6C). In addition 
to the maturation markers, the release of type I IFN was 
strongly upregulated by CpG-P (Supplementary Figure 1). 
Altogether, our RNA-seq method suggests CpG-P as a 
strong adjuvant for pDCs.
DISCUSSION
In this study, we aimed to evaluate the efficiency of 
two novel clinical grade adjuvants in a comprehensive and 
unbiased manner. We therefore used RNA-seq to evaluate 
the effects of each stimulus on total gene expression in two 
DC subsets of interest for immunotherapy. This approach 
allowed us to directly and extensively compare the effects of 
different adjuvants on DC phenotypes, beyond conventional 
maturation markers [40]. With our approach we translated 
changes on the whole-transcriptome level to possibly 
functionally relevant effects. Firstly, the results revealed 
the effect of different stimuli in each donor and allowed us 
to draw conclusions based on these patterns. Secondly, the 
similarity of the results in all three donors indicated good 
reproducibility of this method. Importantly, we were able to 
confirm RNA-seq expression changes regarding maturation 
marker expression and cytokine release on protein level and 
therefore validate the expression differences we observed 
in the transcriptome. This allowed us to draw conclusions 
about the efficacy of the tested clinical grade stimuli.
The PCoA analysis generated a useful initial 
summary of the whole-transcriptome data into a 
simplified representation that nevertheless revealed 
striking relations between the individual datasets. 
Importantly, this approach allowed for an overall 
assessment of the “strength” of each stimulus. This 
analysis suggested that pRNA is potentially a stronger 
pDC stimulus than FSME, with qualitatively similar 
effects as indicated by the GO analysis (Table 1). We 
demonstrated in a previous study that pRNA–induced 
activation of CD1c+ mDCs leads to significantly higher 
IL12p70 release and a similar TNF-α production as R848 
term ontology N genes N up/down - log_10 p-value
immune system process BP 2576 222 23.1
cytokine activity MF 218 51 22.3
response to type I interferon BP 85 33 22.2
defense response to virus BP 325 62 22.0
response to external biotic stimulus BP 869 107 21.4
response to other organism BP 869 107 21.4
type I interferon signaling pathway BP 84 32 21.2
cellular response to type I interferon BP 84 32 21.2
Changes in gene expression clusters were detected by performing a GO term analysis. Of each stimulus the top 10 most 
differential expressed gene clusters were selected. The description for each gene cluster is mentioned in the columns. 
The ontology defines the sub-ontology: molecular function (MF), cellular component (CC) and biological process (BP). 
N genes stands for the total amount of genes for this gene cluster and N up/down for the number of genes that changed 
their expression values upon the stimulus. The table is sorted on the –log10 p-value, which can be found in the column on 
the very right.
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and Poly IC, combined with lower immunosuppressive 
IL-10 production [30]. The robustness of these findings 
was corroborated by our functional assays on protein 
level. Additionally, based on PCoA, CpG-P was identified 
as a potentially strong stimulus for pDCs. Our functional 
assays confirmed this finding by showing that CpG-P not 
only upregulated the maturation markers significantly 
more than the other stimuli, it also led to a very high 
release of immunostimulatory cytokines such as IFN-α. 
Since type I IFNs are known to play important roles in T 
Figure 3: Stimuli effects on individual genes. A-D. Volcano plots representing the gene expression changes (x-axis: log fold) 
together with the statistical significance (y-axis: -10log p-value). Each condition was compared to the respective unstimulated cell type. 
Genes with a log fold change of more than 10 were labeled with the gene name. A) GM-CSF stimulated CD1c+ mDC; B) pRNA stimulated 
CD1c+ mDCs; C) FSME stimulated pDCs; D) pRNA stimulated pDCs.
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cell activation, these findings suggest that CpG-P could 
prove to be a potent pDC stimulus in immune therapies 
[42]. Interestingly, the transcriptome changes by CpG-P 
stimulation are very similar to the ones induced by 
pRNA, even though they stimulate different TLRs.
GM-CSF is widely used to differentiate in vitro 
monocytes into DCs and its high levels are connected 
to higher numbers of moDCs in vivo [43-47]. However, 
GM-CSF has been shown to inhibit pDC development 
via IRF8 [48]. GO-analysis of the effect of GM-CSF on 
CD1c+ mDC indicated that upon GM-CSF stimulation, 
a significant number of genes belonging to the GO 
term “nuclear-transcribed mRNA catabolic process, 
nonsense-mediated decay (NMD)” were differentially 
expressed. This NMD pathway activates the destruction 
of mRNAs containing premature stop codons, which 
has negative side effects [49, 50]. How this pathway 
affects the maturation process of CD1c+ mDCs and 
their functionality has not been reported yet, but it 
may be involved in inflammatory processes [51]. An 
unexpected side-effect like this would not have been 
found by using FACS analysis on an a priori defined, 
limited set of genes. This should be considered when 
GM-CSF is clinically applied, as inducing this gene 
cluster may have a negative impact on CD1c+ mDC 
function.
Other studies have already applied RNA-seq to 
characterize DCs upon stimulation with antigen. For 
example, two recent studies have applied single cell 
RNA-seq in a non-clinical context to identify differences 
between DC subsets and the effect of pathogenic stimuli 
on these cells [52, 53]. Furthermore, there is considerable 
interest to apply RNA-seq in the clinic for diagnostic 
purposes, with several applications already underway 
[54]. Complementing these efforts, our study highlights 
the usefulness of RNA-seq based approaches for the 
Figure 4: High type I/III interferon production of pDCs upon pRNA stimulation. A. Heat map of the type I/III interferon genes. 
Red colour represents high expression and blue low expression. B. Type I interferon levels on protein level measured in the supernatant of 
the stimulated cells after an overnight incubation (n=7).
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Figure 5: Pro-and anti-inflammatory cytokine release by CD1c+ mDCs and pDCs. A. RNA expression values of several 
pro-inflammatory (IL-12p70, TNF-α, IL-23 and IL6) and anti-inflammatory cytokines (IL-10 and TGF-β) of pDCs and CD1c+ mDCs. 
B. IL-12p70 and TNF-α levels on protein level were measured in the supernatant of the stimulated cells after overnight incubation 
(n=3).
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design of clinical therapies, as it allows to determine the 
effects of certain stimuli on the target cells. In addition 
to RNA-seq, proteomics is another powerful unbiased 
approach that can be used to study the differences 
between DC subsets [55].
Taken together, a whole-transcriptome approach 
was used to analyze the effect of clinical grade stimuli 
on human DCs. This method provides a global, unbiased 
overview of how cells react to certain stimuli. In our 
case, we could confirm pRNA as a potent stimulus for 
both pDCs and CD1c+ mDCs and introduce CpG-P as a 
new clinical grade stimulus for pDCs. In vitro, both new 
stimuli outperformed or had clear advantages over the 
existing stimuli.
Figure 6: Assessment of CpG-P as a clinical-grade stimulus. A. PCoA of pDCs of donor 2 and 3 with CpG-P data included in the 
figure. Each point represents the transcriptome of the respective condition and the analysis was based on the first and second coordinate. 
B. Upregulation of the maturation markers on pDCs at RNA-seq level upon indicated stimuli (n=2). Upregulation of the maturation markers 
on pDCs at protein level upon the indicated stimuli (n=7).
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MATERIALS AND METHODS
Cell isolation and culture
For functional assays, DCs were isolated from 
buffy coats of healthy volunteers (Sanquin, Nijmegen, 
the Netherlands) after obtaining written informed 
consent per the Declaration of Helsinki and according 
to institutional guidelines. For RNA-seq measurements, 
cells were obtained from aphaeresis of 3 different 
donors. Peripheral blood mononuclear cells (PBMCs) 
were isolated by using Ficoll density centrifugation 
(Lymphoprep; Axis-Shield PoC AS, Oslo, Norway). 
CD1c isolation kit of Miltenyi Biotec (Bergisch-
Gladbach, Germany) was used to obtain CD1c+ mDCs, 
by following manufacturer’s instructions. Subsequently, 
monocytes were depleted by either plastic adhesion, 
or by the use of CD14 microbeads (Miltenyi Biotec). 
Next, pDCs were purified by positive selection using 
anti–BDCA-4–conjugated magnetic microbeads 
(Miltenyi Biotec). DCs were cultured in X-VIVO-15 
medium (Lonza, Basel, Switzerland) supplemented 
with 2% human serum (Sanquin). DCs were stimulated 
with: FSME (5%; Baxter AG, Vienna), pRNA (15µg/
ml), CpG-P (5µg/ml; Miltenyi Biotech, Germany), 
GM-CSF (800 U/ml; (Cellgenix, Freiburg, Germany). 
pRNA complexes were prepared fresh 5-10 minutes 
before adding to the cell culture. pDCs were cultured 
with 10 ng/mL IL-3 (Cellgenix, Freiburg, Germany) as 
a survival factor in addition to the stimuli.
Protamine-RNA complexes
pRNA complexes were made freshly before 
adding to the cells. Protamine (protaminehydrochloride 
MPH 5000 IE/ml; Meda Pharma BV Amstelveen, 
the Netherlands) was diluted to 0.5 mg/ml in RNase 
free water and mixed with 2-kbp-long single-stranded 
mRNA (coding for gp100). It was extensively mixed and 
incubated for 5-10 minutes at room temperature, before 
added to the cells.
FACS phenotyping
The phenotype of pDC and CD1c+ mDC 
populations was determined by flow cytometry. DC 
purity was assessed by double staining CD11c+/CD1c+ 
for CD1c+mDCs (above 95%) and BDCA2/CD123 
for pDCs (above 95%; all Miltenyi Biotec) [56]. The 
following primary monoclonal antibodies (mAbs) were 
used to determine the maturation state of the DCs: 
anti–CD80-APC, anti–PD-L1-APC (all BD Bioscience 
Pharmingen, San Jose, CA); and anti–CD40-PE 
(Beckman Coulter, Marseille, France). Measurements 
were performed on FACSCalibur and FACSVerse 
flowcytometers (BD).
Cytokine detection
Supernatant was taken from each sample after 
overnight incubation and analyzed with standard sandwich 
ELISAs detecting IFN-α (Bender Medsystems, Vienna, 
Austria).
RNA sequencing
CD1c+ mDCs and pDCs were isolated as described 
above and total RNA was extracted using Trizol 
(Invitrogen, MA, USA), following the standard protocol. 
The quality control of the isolated RNA (concentration, 
RIN, 28S/18S and size) was performed with Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, USA). 
RNA sequencing and read alignment were performed 
by BGI TECH SOLUTIONS (Hong Kong). Reads were 
aligned to human genome version 19. RNA sequencing 
data is deposited at the Gene Expression Omnibus (GEO; 
accession number: GSE89442).
Hierachical clustering
Data was transformed to log values for performing 
hierarchical clustering analysis using the standard settings 
of the GENE-E software (Broad institute, Cambrige, MA; 
http://www.broadinstitute.org/cancer/software/GENE-E/
index.html).
Statistical analysis
Data was analyzed using the R platform for 
statistical computing. Specifically, the package “edgeR”, 
version 3.12, was used for whole-transcriptome principal 
coordinates analysis (using the “plotMDS” command), 
differential expression analysis, and GO term analysis 
[57]. Differential expression was determined by fitting a 
generalized linear model using the “glmFit” command, 
and significance was determined using the likelihood ratio 
test provided by the “glmLRT” command [58]. The R 
scripts used to perform the data analysis are available as 
Supporting Information for this manuscript.
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